tirzepatide weight loss effectiveness compared to semaglutide as with for the Treatment of Obesity GLP-1 Medications for Weight Loss:

Nicholls, MBBS, PhD, director of the Monash Victorian Heart Institute and professor of cardiology at Monash University in Melbourne, Australia, and colleagues randomly assigned 13,165 participants with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD) to a maximum tolerated dose of 5 mg, 10 mg or 15 mg once-weekly subcutaneous tirzepatide (Mounjaro, Eli Lilly) or 1.5 mg of once-weekly subcutaneous dulaglutide (Trulicity, Eli Lilly) with sham dose escalation

pooled safety database: Schneck CPT:PSP 2024

Do not repeatedly cycle the vial between fridge and room temperature

Our program includes access to mental health professionals who can provide guidance and support, helping you navigate emotional challenges and maintain a positive mindset

This means the medication gets delivered just under your skin, into the layer of fatty tissue as opposed to deep into the muscle

Retatrutide appears to produce the fastest weight loss trajectory, with participants in Phase 2 trials losing 24.2% of body weight in just 48 weeks, a pace that outstrips semaglutide and tirzepatide over comparable timeframes